4314-21-0

Usage

Uses

Used in Pharmaceutical Industry:
1H-1,2,3-Triazole-1-acetic acid ethyl ester is used as a precursor in the synthesis of various bioactive molecules for the development of new drugs. Its unique chemical structure allows for the creation of a diverse range of pharmaceutical compounds with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 1H-1,2,3-Triazole-1-acetic acid ethyl ester serves as a key intermediate in the production of various agrochemicals, including pesticides and herbicides. Its involvement in the synthesis process contributes to the development of effective and targeted agricultural solutions.
Used in Organic Material Preparation:
1H-1,2,3-Triazole-1-acetic acid ethyl ester is utilized in the preparation of organic materials, where its chemical properties contribute to the formation of novel materials with specific properties and applications.
Used in Heterocyclic Compound Synthesis:
As a building block in the synthesis of heterocyclic compounds, 1H-1,2,3-Triazole-1-acetic acid ethyl ester plays a crucial role in the development of complex organic molecules with diverse applications in various fields, including pharmaceuticals, materials science, and agrochemicals.
Used in Antifungal and Antimicrobial Applications:
Due to its potential antifungal and antimicrobial properties, 1H-1,2,3-Triazole-1-acetic acid ethyl ester is employed in the development of new medical treatments, particularly for infections caused by resistant strains of fungi and bacteria. Its incorporation into pharmaceutical formulations can enhance the effectiveness of treatments and contribute to the fight against antibiotic resistance.

InChI:InChI=1/C4H7N5O2/c1-2-11-4(10)3-9-7-5-6-8-9/h2-3H2,1H3

Upstream product

• 637-81-0 ethyl-2-azidoacetate 
• 1829-60-3 dimethyl 7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate 
• 105-36-2 ethyl bromoacetate 
• 288-36-8 1 ,2,3-Triazole 
• 288-36-8 1,2,3-triazole 
• 74-86-2 acetylene 

Downstream Products

• 1154097-71-8 t-butyl 6-(5-oxo-4-(1H-1,2,3-triazol-1-yl)-2,5-dihydro-1H-pyrazol-1-yl)nicotinate 
• 1192674-65-9 ethyl (2E/Z)-3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate 
• 1021869-28-2 methyl 3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate 
• 501031-45-4 ethyl 3-(4-bromophenyl)-2-(1H-1,2,3-triazol-1-yl)propanoate 

Relevant academic research and scientific papers

New crystal forms of dihydropyrazolone compound and preparation method of new crystal form

The invention relates to new crystal forms of a dihydropyrazolone compound and a preparation method of the new crystal form. Specifically, the invention relates to a crystal form A and a crystal formB of 1-(6-(2-oxa-8-azaspiro [4.5] decane-8-yl) pyrimidine-4-yl)-4-(1H-1, 2, 3-triazole-1-yl)-1, 2-dihydro-1H-pyrazole-3-sodium phenolate. The preparation method comprises the following steps: preparing 2-(6-(2-oxa-8-azaspiro [4.5] decane-8-yl) pyrimidine-4-yl)-4-(1H-1, 2, 3-triazole-1-yl)-1, 2-dihydro-3H-pyrazole-3-one into a sodium salt in an organic solvent, and crystallizing, thereby obtainingthe product. The new crystal forms of the dihydropyrazolone compound can be used to prevent and/or treat diseases associated with PHD activity.

New crystal forms of PHD inhibitor and preparation method thereof

The invention relates to new crystal forms of a PHD inhibitor and a preparation method of the new crystal forms. Specifically, the invention relates to a crystal form A and a crystal form B of 1-(6-(7-oxa-2-azaspiro [3.5] non-2-yl) pyrimidine-4-yl)-4-(1H-1, 2, 3-triazole-1-yl)-1, 2-dihydro-3H-pyrazole-3-sodium phenolate. The preparation method comprises the following steps: preparing 2-(6-(7-oxa-2-azaspiro [3.5] non-2-yl) pyrimidine-4-yl)-4-(1H-1, 2, 3-triazole-1-yl)-1, 2-dihydro-3H-pyrazole-3-one into a sodium salt in an organic solvent, and crystallizing, thereby obtaining the product. It can be used to prevent and/or treat diseases associated with PHD activity.

Dihydropyrazolone compound as well as preparation method and medical application thereof

The invention relates to a dihydropyrazolone compound as well as a preparation method and medical application thereof, in particularly relates to a general formula (I) compound shown in the specification, as well as a preparation method thereof, a pharmaceutical composition containing the compound, and application of the compound as a proline hydroxylase (PHD) inhibitor, the compound and the pharmaceutical composition containing the compound can be used in treating and/or preventing of PHD -activity- related diseases such as cardiovascular diseases, chronic kidney disease, anemia, wounds, cancer, autoimmune diseases and the like. In the general formula (I), the definition of each substituent in the formula is the same as that in the specification.

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS

Compounds of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, their preparation, and use in treating a bacterial infection are disclosed.

Potent and selective triazole-based inhibitors of the hypoxia-inducible factor prolyl-hydroxylases with activity in the murine brain

As part of the cellular adaptation to limiting oxygen availability in animals, the expression of a large set of genes is activated by the upregulation of the hypoxia-inducible transcription factors (HIFs). Therapeutic activation of the natural human hypoxic response can be achieved by the inhibition of the hypoxia sensors for the HIF system, i.e. the HIF prolylhydroxylases (PHDs). Here, we report studies on tricyclic triazole-containing compounds as potent and selective PHD inhibitors which compete with the 2-oxoglutarate co-substrate. One compound (IOX4) induces HIFα in cells and in wildtype mice with marked induction in the brain tissue, revealing that it is useful for studies aimed at validating the upregulation of HIF for treatment of cerebral diseases including stroke.

METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS

The present invention relates to a process for preparing 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol (I—enol form) or 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one (I—keto form) and sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (II) from 1,2,3-triazole (III), methyl bromoacetate (IV-Me-Br) or ethyl bromoacetate (IV-Et-Br), 4,6-dichloropyrimidine (VIII), morpholine (IX) and hydrazine (XII).

Water-soluble NHC-Cu catalysts: Applications in click chemistry, bioconjugation and mechanistic analysis

Copper(i)-catalyzed 1,3-dipolar cycloaddition of azides and terminal alkynes (CuAAC), better known as "click" reaction, has triggered the use of 1,2,3-triazoles in bioconjugation, drug discovery, materials science and combinatorial chemistry. Here we report a new series of water-soluble catalysts based on N-heterocyclic carbene (NHC)-Cu complexes which are additionally functionalized with a sulfonate group. The complexes show superior activity towards CuAAC reactions and display a high versatility, enabling the production of triazoles with different substitution patterns. Additionally, successful application of these complexes in bioconjugation using unprotected peptides acting as DNA binding domains was achieved for the first time. Mechanistic insight into the reaction mechanism is obtained by means of state-of-the-art first principles calculations.

SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES

The invention relates to dihydropyrazolon-derivatives of formula (I), to methods for their production, to their use for treating and/or for preventing diseases and their use for producing medicaments for treating and/or for preventing diseases, in particular cardiovascular and haematological diseases, kidney diseases and for promoting the healing of wounds.

SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.